Charles River Laboratories (CRL)

NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-15

$300.15-1.99%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Charles River Laboratories’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.6%

+10% or more+5%0%−5%−10% or less

12.73 → 12.82 EPS · FY ending Dec 27, 2027 · 10 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 10 to 10; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS near $11.3 or better	The company expects EPS near $11.3 in 2026 and repurchased $200 million of stock in Q1.	Intact	EPS falls below $10.8 in FY26	Diluted EPS: $-0.03 per share FY2026-Q2; GAAP. Published target: >= $10.8 per share. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-0.03 USD/share · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 27, 2026 Source: company_financial_results. Reference: 2c78599f-7b6a-4355-81e5-8bee74be06bd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth near flat or better	A primary condition in Charles River Laboratories's published investment case. The stated target is >= -1.5% YoY.	Intact	YoY revenue growth falls below -1.5% in FY26	Revenue growth: -2.72% FY2026-Q2; GAAP. Published target: >= -1.5% YoY. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-2.718346 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 27, 2026 Source: company_financial_results. Reference: 2c78599f-7b6a-4355-81e5-8bee74be06bd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. The Company completed divestitures of CDMO and Cell Solutions businesses in 2026-Q1 and certain European Discovery Services sites in 2026-Q2. Revenue declined 2.7% year-over-year in 2026-Q2, with Manufacturing segment revenue down 6.3% due to the CDMO divestiture. Management has consistently emphasized refining the portfolio through divestitures, and the financials show delivery on this priority. Delivery assessment Oct 15, 2026
Continue stock repurchases of at least $200 million in Q1	The company expects EPS near $11.3 in 2026 and repurchased $200 million of stock in Q1.	Intact	Stock repurchases fall significantly below $200 million in Q1 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. The Company repurchased $200 million in 2026-Q1 and $100 million in 2026-Q2, totaling $300 million year-to-date, with $700 million remaining under the $1.0 billion authorization. Management has consistently emphasized share repurchases, and the financial data confirms ongoing execution. Delivery assessment Oct 15, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-27 · fmp

FY2027 EPS$12.82

$12.35 → $12.82 · observed estimates

FY2027 revenue$4.01B

$3.92B → $4.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$12.35	$3,918,241,773	10 / 12
2026-07-25	$12.35	$3,918,241,773	10 / 12
2026-07-26	$12.35	$3,918,241,773	10 / 12
2026-07-27	$12.35	$3,918,241,773	10 / 12
2026-07-28	$12.35	$3,918,241,773	10 / 12
2026-07-29	$12.35	$3,918,241,773	10 / 12
2026-07-30	$12.35	$3,918,241,773	10 / 12
2026-07-31	$12.35	$3,918,241,773	10 / 11
2026-08-01	$12.35	$3,918,241,773	10 / 11
2026-08-02	$12.35	$3,918,241,773	10 / 11
2026-08-03	$12.35	$3,918,241,773	10 / 11
2026-08-04	$12.35	$3,918,241,773	10 / 11
2026-08-05	$12.35	$3,918,241,773	10 / 11
2026-08-06	$12.35	$3,918,241,773	10 / 11
2026-08-07	$12.55	$3,943,826,674	9 / 11
2026-08-08	$12.55	$3,943,826,674	9 / 11
2026-08-09	$12.55	$3,943,826,674	9 / 11
2026-08-10	$12.55	$3,943,826,674	9 / 11
2026-08-11	$12.55	$3,943,826,674	9 / 11
2026-08-12	$12.55	$3,943,826,674	9 / 11
2026-08-13	$12.55	$3,943,826,674	9 / 11
2026-08-14	$12.55	$3,943,826,674	9 / 11
2026-08-15	$12.55	$3,943,826,674	10 / 11
2026-08-16	$12.55	$3,943,826,674	10 / 11
2026-08-17	$12.55	$3,943,826,674	10 / 11
2026-08-18	$12.55	$3,943,826,674	10 / 11
2026-08-19	$12.55	$3,943,826,674	10 / 11
2026-08-20	$12.73	$3,986,576,968	10 / 11
2026-08-21	$12.73	$3,986,576,968	10 / 11
2026-08-22	$12.73	$3,986,576,968	10 / 11
2026-08-23	$12.73	$3,986,576,968	10 / 11
2026-08-24	$12.73	$3,986,576,968	10 / 11
2026-08-25	$12.73	$3,986,576,968	10 / 11
2026-08-26	$12.73	$3,986,576,968	10 / 11
2026-08-27	$12.73	$3,986,576,968	10 / 11
2026-08-28	$12.73	$3,986,576,968	10 / 11
2026-08-29	$12.73	$3,986,576,968	10 / 11
2026-08-30	$12.73	$3,986,576,968	10 / 11
2026-08-31	$12.73	$3,986,576,968	10 / 11
2026-09-01	$12.73	$3,986,576,968	10 / 11
2026-09-02	$12.73	$3,986,576,968	10 / 11
2026-09-03	$12.73	$3,986,576,968	10 / 11
2026-09-04	$12.73	$3,986,576,968	10 / 11
2026-09-05	$12.73	$3,986,576,968	10 / 11
2026-09-06	$12.73	$3,986,576,968	10 / 11
2026-09-07	$12.73	$3,986,576,968	10 / 11
2026-09-08	$12.73	$3,986,576,968	10 / 11
2026-09-09	$12.73	$3,986,576,968	10 / 11
2026-09-10	$12.73	$3,986,576,968	10 / 11
2026-09-11	$12.73	$3,986,576,968	10 / 11
2026-09-12	$12.73	$3,986,576,968	10 / 11
2026-09-13	$12.73	$3,986,576,968	10 / 11
2026-09-14	$12.73	$3,986,576,968	10 / 11
2026-09-15	$12.73	$3,986,576,968	10 / 11
2026-09-16	$12.73	$3,986,576,968	10 / 11
2026-09-17	$12.73	$3,986,576,968	10 / 11
2026-09-18	$12.73	$3,986,576,968	10 / 11
2026-09-19	$12.73	$3,986,576,968	10 / 11
2026-09-20	$12.76	$3,986,576,968	10 / 11
2026-09-21	$12.76	$3,986,579,367	10 / 11
2026-09-22	$12.75	$3,987,347,984	11 / 11
2026-09-23	$12.76	$3,987,347,984	11 / 11
2026-09-24	$12.76	$3,987,347,984	11 / 11
2026-09-25	$12.77	$3,989,492,269	10 / 11
2026-09-26	$12.76	$3,988,410,681	10 / 11
2026-09-27	$12.76	$3,988,410,681	10 / 11
2026-09-28	$12.74	$3,991,024,346	10 / 11
2026-09-29	$12.74	$3,991,024,382	10 / 11
2026-09-30	$12.74	$3,991,024,382	10 / 11
2026-10-01	$12.78	$3,993,533,030	10 / 12
2026-10-02	$12.78	$3,993,533,030	10 / 12
2026-10-03	$12.78	$3,993,533,030	10 / 12
2026-10-04	$12.78	$3,993,533,030	10 / 12
2026-10-05	$12.78	$3,993,533,030	10 / 12
2026-10-06	$12.78	$4,002,733,030	10 / 12
2026-10-07	$12.78	$4,002,746,363	10 / 12
2026-10-08	$12.82	$4,010,618,682	10 / 12
2026-10-09	$12.82	$4,010,613,030	10 / 12
2026-10-10	$12.82	$4,010,613,030	10 / 12
2026-10-11	$12.82	$4,010,613,030	10 / 12
2026-10-12	$12.82	$4,010,613,030	10 / 12
2026-10-13	$12.82	$4,010,613,030	10 / 12
2026-10-14	$12.82	$4,013,437,446	10 / 12
2026-10-15	$12.82	$4,013,437,446	10 / 12

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	13	5	1
2026-06-01	14	3	2
2026-07-01	14	3	1
2026-08-01	13	3	1
2026-09-01	15	2	1
2026-10-01	15	2	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 15 Buy / Strong Buy · 2 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades9 maintains

Recent actions · Sep 16–Oct 15 · 9 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Morgan StanleyOct 12 · prior Aug 7

$300.00 → $340.00+13.3%

UBSSep 30

$357.00New observation · no comparable prior

JefferiesSep 28

$340.00New observation · no comparable prior

Robert W. BairdSep 25 · prior Aug 6

$291.00 → $334.00+14.8%

RBC CapitalSep 25 · prior Aug 6

$282.00 → $322.00+14.2%

Mizuho SecuritiesSep 25 · prior Aug 10

$264.00 → $295.00+11.7%

Evercore ISISep 25 · prior Sep 11

$320.00 → $330.00+3.1%

Deutsche BankSep 25

$320.00New observation · no comparable prior

BarclaysSep 25 · prior Aug 5

$300.00 → $330.00+10.0%

Argus ResearchSep 17

$330.00New observation · no comparable prior

$0$196.35$392.70

6 raises · 0 cuts · 0 unchanged · 4 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS near $11.3 or betterDiluted EPS: $-0.03 per share
Revenue growth near flat or betterRevenue growth: -2.72%
Continue stock repurchases of at least $200 million in Q1Direct metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-33.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Charles River Laboratories outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on refining its portfolio and enhancing client experience. The current thesis state is intact, supported by recent earnings beats and a strong financial performance relative to its industry.

What's priced into Charles River Laboratories

The market appears to have priced in a justified valuation, reflecting a premium compared to peers. There is a low expectations gap, indicating that current performance is largely in line with what investors anticipate.

What the fundamentals likely do

Fundamentals are likely to remain strong, supported by management's focus on stock repurchases and divestitures. However, organic revenue growth has been flat to slightly negative, which may limit broader revenue impact in the near term.

What Charles River Laboratories hinges on

The thesis hinges on management's ability to execute on divestitures and enhance client relationships. Additionally, sector momentum from key players like TMO, DHR, and NTRA will be crucial for sustaining positive performance.